FDA Officially Resolves Semaglutide Injection Shortage
The FDA announced that the semaglutide injection shortage has been officially resolved, which changes the legal basis for some compounding of semaglutide products.
Key Takeaways
- Semaglutide injection shortage officially resolved in February 2026
- Changes the legal basis for 503B outsourcing facility compounding
- 503A pharmacy compounding with individual prescriptions remains legal
- Transition timeline depends on litigation and FDA enforcement
What Happened
On February 21, 2026, the FDA announced that the semaglutide injection shortage has been officially resolved. This means that Novo Nordisk can now supply adequate quantities of Ozempic and Wegovy to meet demand.
Why This Matters
Under federal law, 503B outsourcing facilities can compound copies of commercially available drugs when those drugs are on the FDA shortage list. With the shortage resolved, the legal basis for some compounding of semaglutide changes. However, 503A pharmacies can still compound semaglutide based on individual patient prescriptions.
Impact on Patients
Patients currently receiving compounded semaglutide from 503B facilities may need to transition to brand-name products or work with their providers to explore continued compounding through 503A pharmacies with valid prescriptions. The transition timeline depends on ongoing litigation and FDA enforcement decisions.
Affected Companies
Empower Pharmacy
503A PharmacyLarge FDA-registered 503B outsourcing facility and compounder with a major national footprint in sterile and non-sterile medication production, including GLP-1-related products.
Empower is frequently relevant because it may be the actual compounding or outsourcing facility behind a telehealth prescription flow.
Olympia Pharmaceuticals
503A PharmacyFDA-registered 503B outsourcing facility specializing in sterile compounding across GLP-1 medications, hormone therapy, and other specialty formulations.
Olympia is a facility-level player in the supply chain rather than a consumer-facing telehealth brand.
Hallandale Pharmacy
503A PharmacyFlorida-based compounder operating across 503B outsourcing and 503A pharmacy functions, with a significant presence in sterile medication fulfillment.
Hallandale matters because it may sit behind the scenes of telehealth GLP-1 fulfillment rather than in front of the patient.
Valor Compounding Pharmacy
503A Pharmacy503B outsourcing facility and compounding pharmacy providing sterile injectable compounds, including semaglutide and tirzepatide formulations.
Valor is a supply-chain and fulfillment name rather than a front-end telehealth destination.
Pavilion Compounding Pharmacy
503A PharmacyAtlanta-based 503B outsourcing facility providing sterile compounded medications for healthcare providers across multiple states.
Pavilion is a backend facility name rather than a consumer acquisition brand.
Source: View original on FDA.gov
Frequently Asked Questions
Can I still get compounded semaglutide?
Yes, through 503A compounding pharmacies with a valid individual prescription. The legal landscape for 503B outsourcing facilities is evolving and depends on ongoing litigation.
Will compounded semaglutide become more expensive?
Pricing may change as the supply chain adjusts. Brand-name semaglutide (Ozempic, Wegovy) remains significantly more expensive than compounded versions, but the availability and pricing of compounded options may shift.
Disclaimer: This article summarizes publicly available FDA data for informational purposes only. It is not medical or legal advice. Always consult your healthcare provider and verify with official FDA sources before making decisions about your treatment.
Related Safety Guides
GLP-1 Safety Alerts
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.